Scarica l'app Stockscreener
1.11
8.82%
0.09
Precedente Chiudi:
$1.02
Aprire:
$1.05
Volume 24 ore:
35,453
Relative Volume:
0.68
Capitalizzazione di mercato:
$44.65M
Reddito:
$13.42M
Utile/perdita netta:
$-73.35M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-56.34M
1 W Prestazione:
+21.64%
1M Prestazione:
+23.47%
6M Prestazione:
-11.20%
1 anno Prestazione:
-67.83%
Intervallo 1D:
$1.02
$1.1144
Intervallo di 1 settimana:
$0.88
$1.25
Portata 52W:
$0.8008
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Nome
Barinthus Biotherapeutics Plc Adr
Settore
Industria
Telefono
44 (0) 1865 818808
Indirizzo
UNIT 6-10, ZEUS BUILDING, DIDCOT
Confronta BRNS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
1.11 | 44.65M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-25 | Iniziato | Jefferies | Buy |
| 2021-05-25 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-25 | Iniziato | William Blair | Outperform |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Borsa (BRNS) Ultime notizie
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Azioni (BRNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):